MA53648A - Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase - Google Patents

Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase

Info

Publication number
MA53648A
MA53648A MA053648A MA53648A MA53648A MA 53648 A MA53648 A MA 53648A MA 053648 A MA053648 A MA 053648A MA 53648 A MA53648 A MA 53648A MA 53648 A MA53648 A MA 53648A
Authority
MA
Morocco
Prior art keywords
glucopyranosidase
desoxy
acetamido
glycoprotein
inhibitors
Prior art date
Application number
MA053648A
Other languages
English (en)
Inventor
Nathan Genung
Ryan Gianatassio
Kevin M Guckian
Edward Yin Shiang Lin
Jeffrey Vessels
Zhili Xin
Lei Zhang
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA53648A publication Critical patent/MA53648A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
MA053648A 2018-09-19 2019-09-18 Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase MA53648A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862733484P 2018-09-19 2018-09-19
US201862750000P 2018-10-24 2018-10-24

Publications (1)

Publication Number Publication Date
MA53648A true MA53648A (fr) 2021-07-28

Family

ID=68073263

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053648A MA53648A (fr) 2018-09-19 2019-09-18 Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase

Country Status (21)

Country Link
US (2) US12180205B2 (fr)
EP (1) EP3853226A1 (fr)
JP (2) JP7606960B2 (fr)
KR (1) KR20210060513A (fr)
CN (2) CN119219621A (fr)
AU (1) AU2019344922B2 (fr)
BR (1) BR112021004739A2 (fr)
CA (1) CA3113009A1 (fr)
CL (1) CL2021000646A1 (fr)
CO (1) CO2021004873A2 (fr)
CR (1) CR20210181A (fr)
IL (2) IL281514B2 (fr)
JO (1) JOP20210036A1 (fr)
MA (1) MA53648A (fr)
MX (1) MX2021003232A (fr)
PE (1) PE20211591A1 (fr)
PH (1) PH12021550439A1 (fr)
SG (1) SG11202102379XA (fr)
TW (1) TWI863926B (fr)
UY (1) UY38376A (fr)
WO (1) WO2020061150A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210060513A (ko) 2018-09-19 2021-05-26 바이오젠 엠에이 인코포레이티드 O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제
EP3643711A1 (fr) 2018-10-24 2020-04-29 Bayer Animal Health GmbH Nouveaux composés anthelminthiques
PE20231168A1 (es) * 2020-08-03 2023-07-26 Biogen Ma Inc Formas cristalinas de un inhibidor de la o-glucoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa
KR102533471B1 (ko) * 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도
WO2025184490A1 (fr) 2024-03-01 2025-09-04 Biogen Ma Inc. N-[4-fluor-5-[[(2s,4r)-4-[(6-méthoxy-4-pyrimidnyl)oxy]-2-méthyl-1-pyrrolidinyl]méthyl]-2-thiazolyl]acétamide destiné à être utilisé dans le traitement de la maladie d'alzheimer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US20040077654A1 (en) 2001-01-15 2004-04-22 Bouillot Anne Marie Jeanne Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
WO2006034341A2 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
US8497265B2 (en) 2010-05-13 2013-07-30 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A1 (fr) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
WO2013078320A1 (fr) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
EP2953941B1 (fr) 2013-02-11 2017-04-05 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
WO2013120104A2 (fr) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, leurs compositions et utilisations
WO2013170072A2 (fr) 2012-05-09 2013-11-14 Neurop, Inc. Composés pour le traitement de troubles neurologiques
RU2672873C2 (ru) 2012-10-31 2018-11-20 Алектос Терапьютикс Инк. Ингибиторы гликозидаз и их применения
SI2970272T1 (sl) * 2013-03-14 2019-06-28 Merck Patent Gmbh Inhibitorji glikozidaze
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (fr) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
CA2934702A1 (fr) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Inhibiteurs de glutaminase
CN105753814A (zh) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
CA3044762A1 (fr) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Composes inhibiteurs d'oga bicyclique
JP2020503298A (ja) * 2016-12-16 2020-01-30 ヤンセン ファーマシューティカ エヌ．ベー． 単環式ｏｇａ阻害剤化合物
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
CN118955490A (zh) 2018-03-14 2024-11-15 渤健马萨诸塞州股份有限公司 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂
US11459324B2 (en) 2018-03-14 2022-10-04 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors
WO2019243531A1 (fr) 2018-06-20 2019-12-26 Janssen Pharmaceutica Nv Composés inhibiteurs d'oga
KR20210060513A (ko) 2018-09-19 2021-05-26 바이오젠 엠에이 인코포레이티드 O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제

Also Published As

Publication number Publication date
TW202031651A (zh) 2020-09-01
CR20210181A (es) 2021-07-01
IL281514B1 (en) 2024-10-01
SG11202102379XA (en) 2021-04-29
CN119219621A (zh) 2024-12-31
WO2020061150A1 (fr) 2020-03-26
KR20210060513A (ko) 2021-05-26
US12275728B2 (en) 2025-04-15
CL2021000646A1 (es) 2021-09-03
JOP20210036A1 (ar) 2021-02-25
US12180205B2 (en) 2024-12-31
TWI863926B (zh) 2024-12-01
BR112021004739A2 (pt) 2021-06-01
US20240308995A1 (en) 2024-09-19
JP7606960B2 (ja) 2024-12-26
MX2021003232A (es) 2021-07-16
IL281514A (en) 2021-04-29
IL315564A (en) 2024-11-01
AU2019344922B2 (en) 2025-02-06
UY38376A (es) 2020-04-30
US20220041586A1 (en) 2022-02-10
AU2019344922A1 (en) 2021-03-25
CN113166137A (zh) 2021-07-23
EP3853226A1 (fr) 2021-07-28
JP2022500472A (ja) 2022-01-04
JP2025011144A (ja) 2025-01-23
PH12021550439A1 (en) 2021-11-29
CO2021004873A2 (es) 2021-07-30
IL281514B2 (en) 2025-02-01
CA3113009A1 (fr) 2020-03-26
PE20211591A1 (es) 2021-08-18
CN113166137B (zh) 2024-08-16

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
MA51616A (fr) Inhibiteurs d'adn-pk
MA54550A (fr) Inhibiteurs de kif18a
EP4007752C0 (fr) Inhibiteurs de kif18a
EP3906026A4 (fr) Inhibiteurs irréversibles de l'interaction ménine-mll
EP3843714C0 (fr) Inhibiteurs de cd73
EP4007756C0 (fr) Inhibiteurs de kif18a
EP4007753C0 (fr) Inhibiteurs de kif18a
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA52413A (fr) Inhibiteurs de cd73
MA51066A (fr) Inhibiteurs d'intégrine
EP3801503A4 (fr) Inhibiteurs de sarm1
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA44725A (fr) Formulations d'un inhibiteur de lsd1
DK3774817T3 (da) Bcl6-hæmmere
EP3787635A4 (fr) Inhibiteurs de cd73
MA52813A (fr) Inhibiteurs de sarm1
MA49006A (fr) Inhibiteurs d'ip6k
EP3817736A4 (fr) Inhibiteurs de pikfyve
MA52809A (fr) Inhibiteurs de sarm1
EP3980011C0 (fr) Inhibiteurs de sarm1
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
MA50906A (fr) Inhibiteurs d'immunoprotéasome